THERAPEUTIC CLASS

Immunotherapy in Lung Cancer

---

Lung cancer is the leading cause of cancer-related mortality in the United States.1 Non–small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases.2 Among patients with NSCLC, approximately 40% present with stage IV disease.
3 Although targeted therapy has been associated with a significant benefit in patients harboring aberrations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1,4–6 these gene abnormalities are present in a small
percentage of patients.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Antineoplastic
Redditux

Specific Detail Info

Hematol Oncol Clin N Am 31 (2017) 131–141

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment